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Abstract
Background: The current prevalence of esophagitis in southern Europe is unknown. In addition, the risk factors for reflux
esophagitis are not fully understood.
Objective: The objective of this article is to assess the prevalence and risk factors for esophagitis in Spain.
Methods: A prospective, observational, cross-sectional, multicenter study (PRESS study) was conducted among 31 gastro-
intestinal endoscopy units throughout Spain. A total of 1361 patients undergoing upper gastrointestinal endoscopy were
enrolled. Sociodemographic, clinical and treatment data were recorded.
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Results: A total of 95% of patients were Caucasian and 52% were male (mean age: 53 17 years). The most frequent
symptoms prompting endoscopy were heartburn (40%), regurgitation (26%) and dysphagia (15%). Fifty-four percent of
patients undergoing endoscopy were receiving proton pump inhibitor (PPI) treatment. Esophagitis (mainly mild-moderate)
was present in 154 (12.4%) patients. The severe form was recorded in only 11 (0.8%) patients. Multivariate analysis results
indicated that the likelihood of esophagitis was higher in men (OR¼ 1.91, 95% CI¼ 1.31–2.78), in patients with high GERD-
Q scores (OR¼ 1.256, 95% CI¼ 1.176–1.343), weight increase (OR¼ 1.014, 95% CI¼ 1.003–1.025) and high alcohol con-
sumption (OR¼ 2.49, 95% CI¼ 1.16–5.36).
Conclusion: Severe esophagitis is a rare finding in the Spanish population. Male gender, high GERD-Q score, weight increase
and high alcohol consumption are main risk factors for its appearance.
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Endoscopy, severe esophagitis, nonsteroidal anti-inflammatory drugs (NSAID), gastro-esophageal reflux disease (GERD),
hiatal hernia, questionnaires, gastrointestinal symptoms, Barrett’s esophagus
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Introduction
Gastroesophageal reflux disease (GERD) is a common
condition that affects about 15%–30% of the popula-
tion.1–5 GERD comprises a wide variety of clinical
manifestations, ranging from reflux symptoms without
visible lesions on conventional endoscopy (non-erosive
reflux disease, NERD) to grossly visible esophagitis
with varying extent of mucosal breaks.6,7
Endoscopy is generally accepted as an important
clinical tool for the identification of esophageal injury
syndromes.8 For patients with esophageal symptoms
unresponsive to adequate empiric therapy, the aim of
the endoscopy is to make a positive diagnosis of
esophagitis and to assess or to rule out other esopha-
geal conditions.8
Data on the current endoscopic prevalence of
esophagitis and severe esophagitis in southern Europe
are scarce. Furthermore, many factors that might influ-
ence the development of these diseases – for example,
the type of predominant diet, tobacco or alcohol con-
sumption, or proton pump inhibitor (PPI) use – have
been steadily changing in recent years. A previous
retrospective study by our group found the prevalence
of esophagitis to be low, appearing in only 8.7% of
93,699 endoscopies reviewed.9
In addition, at present, it is not fully understood
which additional risk factors contribute to the develop-
ment of reflux esophagitis or what influence these fac-
tors might have on disease severity. Possible risk factors
reported include overweight, male gender, history of
GERD, smoking habit, absence of Helicobacter pylori
or presence of hiatal hernia.1–3,10–13 As far as severe
esophagitis is concerned, the clinical data suggest a rela-
tionship with severity of symptoms, presence of heart-
burn for more than five years, obesity, presence of
hiatal hernia, male gender and Caucasian ethnicity.14,15
Finally, the role of drugs in the pathogenesis of
severe esophagitis is especially controversial and has
been only partially evaluated. While the use of PPIs is
considered to be a protective factor,11,16 the role of
other drugs such as anticholinergics,17 nitrates11,18
and tricyclic antidepressants, calcium antagonists or
sulcralfate11 is more debatable. In particular, the results
of studies of the effect of nonsteroidal anti-inflamma-
tory drugs (NSAIDs) have been contradictory.15,18–20
In this context, we assessed the prevalence and risk
factors of esophagitis, and specifically the role of
NSAIDs, in an observational, cross-sectional, nation-
wide, multicenter study (Prevalence and Risk factors
for Esophagitis in Spain (PRESS)).
Methods
Study design
From January to December 2009, an observational,
cross-sectional, nationwide, multicenter study (PRESS
study) was conducted in the context of the routine clin-
ical practice of gastroenterologists from gastrointestinal
endoscopy units at 31 Spanish National Health Service
and private centers (Figure 1). Hospitalized patients or
outpatients from primary care or specialist settings who
underwent upper gastrointestinal endoscopy were
enrolled.
Once a month, on a randomly selected working day,
all patients undergoing an upper gastrointestinal endos-
copy were evaluated for inclusion in the study. Patients
who agreed to participate underwent a clinical inter-
view and a clinical exploration, and socio-demographic
and clinical data were recorded. Socio-demographic
characteristics included sex, age, ethnicity, place of
birth, socioeconomic status, weight, height, abdominal
perimeter, alcohol consumption and tobacco use.
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Clinical characteristics included clinical history of
GERD (frequency and severity of typical symptoms of
heartburn, regurgitation and dysphagia, and time from
onset), previous diagnosis of reflux disease, esophagitis
and Barrett’s esophagus, comorbidities, current treat-
ments and indication for endoscopy. Moreover, before
the procedure, the patient was asked to complete two
self-administered questionnaires: the general question-
naire named ‘‘Gastrointestinal Symptom Rating Scale’’
(GSRS), modified for patients with upper gastrointes-
tinal disorders21 and GERD-Q, the specific question-
naire for assessing GERD.22
The GSRS includes 15 items for the description of
gastrointestinal symptoms.21 GERD-Q includes six
items for scoring the number of days with symptoms
and the use of over-the-counter (OTC) medications
during the previous seven days.22,23 Six symptoms,
including heartburn, regurgitation, and upper abdom-
inal pain, were evaluated for frequency on a four-point
Likert scale. A cut-off score of 8 points has the highest
specificity and sensitivity when testing for GERD.24
Information on treatment was collected by struc-
tured interview before the procedure. The medication
taken during the last month was recorded, with a spe-
cific register of NSAIDs, acetyl salicylic acid (AAS) and
other antiplatelet drugs, PPIs and histamine H2-
receptor antagonists. In all cases, the name of the
drug and medicinal product, posology and period of
treatment were recorded. If necessary, data were con-
firmed after the procedure by telephone.
During the procedure, endoscopic findings were rec-
orded. Esophagitis was diagnosed and classified
according to the Los Angeles classification (LAC).25
The presence and size (cm) of hiatal hernia was
recorded and other lesions were briefly described. H.
pylori determination was not mandatory. The decision
of whether H. pylori study was necessary and the choice
of the method for investigating the infection were left to
the criteria of the endoscopist.
Statistical analysis
In the statistical analysis, frequency tables, percentages
and 95% confidence intervals (95% CIs) were obtained
for categorical variables, while measures of central
tendency and dispersion were calculated for continuous
variables (mean, standard deviation (SD), standard
error (SE), minimum and maximum and 95% CIs,
median and quartiles Q1 and Q3). For analysis,
weight and height were stratified according to sex.
Abdominal perimeter was considered to be increased
when it was above 101 cm in males and 88 cm in
females.26 Alcohol intake was considered significant
when it was more than 20 drinks per week. Smoking
was considered significant when patients consumed 10
or more cigarettes per day and major when they con-
sumed 20 or more cigarettes per day.
The chi-square test was used to compare qualitative
variables between groups, and non-parametric tests and
analysis of variance (ANOVA) were used to compare
quantitative variables.
Univariate and multivariate logistic regressions
(stepwise method) were performed to determine
which factors were associated with esophagitis and,
particularly, with severe esophagitis. Finally, the
Hosmer-Lemeshow test was performed to establish
Figure 1. Geographical distribution of participating centers.
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the goodness of fit of the models. In all cases, statistical
significance was defined as a p value less than 0.05, and
the statistical analysis was performed using SPSS v.21.0
(IBM Corp. Chicago, IL, USA).
Sample size calculation
A sample size of 1300 patients was calculated a priori as
sufficient for detecting a minimum increase in odds
ratio (OR) of 1.5 related to NSAID use, with an
alpha level of 0.05 and a beta level of 0.20.
Ethics statement
The study was reviewed and approved by the ethics com-
mittees of both the Hospital Universitario La Fe
(Valencia, Spain) and the Corporacio´ Universita`ria
Sanita`ria Parc Taulı´ (Sabadell, Spain). Written informed
consent was obtained from all participants. Data were
coded in order to avoid patient identification and man-
aged in accordance with the Spanish ‘‘Ley de Proteccio´n
de Datos de Cara´cter Personal’’ (https://www.boe.es/
buscar/pdf/1999/BOE-A-1999-23750-consolidado.pdf).
Results
Thirty-one gastroenterology units at Spanish hospitals
participated in the study, and 1361 patients undergoing
upper gastrointestinal endoscopy were enrolled. The
majority of patients (94.80%) were Caucasian and
51.9% were male, with a mean age of 53.03 17.12
years (range: 14–96 years). Mean abdominal perimeter
was 96.18 14.86 cm and 86.20 16.25 cm for men and
women, respectively; mean height was 171.38 7.90 cm
for men and 159.73 7.09 cm for women, and mean
weight was 77.59 13.33 kg for men and
66.26 16.43 kg for women. Mean body mass index
(BMI) was 26.22 5.56 kg/m2 (2% underweight, 42%
normal, 26% overweight and 29% obese). Twenty-
three percent of patients were smokers, with a mean
of 14.04 10.36 cigarettes per day, and 22.5% alcohol
consumers, with a mean of 2.12 7.64 units/week
(see baseline characteristics in Table 1). Three percent
of patients reported alcohol use of more than 20 units/
week.
A total of 225 patients (16.5%) presented with clinical
diagnosis of GERD previous to endoscopy. Mean time
from symptoms onset was 73.0 90.5 days (range: 1–502
days) (Table 1). The most frequent symptoms prompting
endoscopy were heartburn (40.1%), regurgitation
(26.1%), dysphagia (15.4%) and thoracic pain (9.3%).
Comorbidities were infrequent, with 88.2% of patients
having a Charlson score of 1 or lower (Table 1).
More than half of the patients were taking PPIs
(continuous or intermittent) (54.4%), while 14.8%
Table 1. Sociodemographic and clinical characteristics of patients
Characteristics n¼ (1361)a
Ethnicity, n (%)
Caucasian 1228 (94.80)
Other 68 (5.20)
Age (years), mean SD 53.03 17.12
Gender, n (%)
Male 632 (48.10)
Female 683 (51.90)
Waist circumference (cm)
Total 90.79 10.58
Men 96.18 14.86
Women 86.20 16.25
Weight (kg), mean SD
Total 71.62 16.10
Men 77.59 13.33
Women 66.26 16.43
Height (cm), mean SD
Total 165.29 9.57
Men 171.38 7.90
Women 159.73 7.09
BMI (kg/m2), mean SD 26.22 5.56
Underweight, n (%) 27 (2.14)
Normal, n (%) 555 (42.2)
Overweight, n (%) 348 (26.4)
Obese, n (%) 386 (29.3)
Smoking habit, n (%) 306 (22.50)
Cigarettes/day, mean SD 14.04 10.36
Alcohol consumption, n (%) 306 (22.50)
Units/week, mean SD 2.12 7.64
Outpatients, n (%) 1230 (90.40%)
Hospitalized patients, n (%) 131 (9.60)
Previous GERD diagnosis, n (%) 225 (16.50)
Time from onset (days), mean SD 73.03 9046
GERD symptoms, n (%)
Heartburn 546 (40.10)
Regurgitation 355 (26.10)
Dysphagia 209 (15.40)
Thoracic pain 127 (9.30)
Charlson score, mean SD 0.4 0.8
Helicobacter pylori infection 108/248 (43.5%)
Esophagitis 154 (12.4%)
Severe esophagitis (LA-D) 11 (0.8%)
Hiatal hernia 373 (27%)
Current treatments, n (%)
PPIs 740 (54.4)
NSAIDs 201 (14.80)
AAS 93 (6.80)
Antidepressant drugs 57 (4.20)
aTotal number might sum less than 1361 because of missing data. AAS:
acetyl salicylic acid; BMI: body mass index; GERD: gastro-esophageal reflux
disease; PPI: proton pump inhibitors; SD: standard deviation; LA-D: Los
Angeles Classification, grade D.
232 United European Gastroenterology Journal 4(2)
were consuming NSAIDs, 6.8% AAS and 4.2%, anti-
depressant drugs (Table 1). Most patients took PPI at a
standard dose either once a day (84%) or twice a day
(16%). Both higher doses or half-doses were exception-
ally used in this series. In addition, less than 5% of the
patients stopped PPI before the endoscopy and, of
them, most stopped the drug for less than 10 days.
Most patients underwent endoscopy on an out-
patient basis (90.40%), and only 9.6% of patients
were hospitalized. Forty-seven percent of patients
reported GERD symptoms immediately before endos-
copy; the most frequent symptom was heartburn.
Esophagitis (mainly mild to moderate) was present
in 154 (12.4%) patients. According to the LAC, 96
patients (66%) were Grade A, 34 (25%) were Grade
B, 13 (10%) were Grade C, and 11 (8%) were Grade
D. H. pylori was evaluated in 248 patients and infection
was present in 108 (43.5%) (Table 1). Hiatal hernia was
strongly associated with esophagitis: 22% of patients
with hiatal hernia had the condition, compared with
only 7% of the patients without hernia.
Results of the univariate statistical analysis showed
that factors such as age, male gender, increased BMI,
weight, height and waist circumference, alcohol
consumption (>20 units/week), and GERD-Q score
were significantly more frequent in patients with
esophagitis (univariate statistical analysis, p 0.05)
(Table 2). The logistic regression model including
these factors indicated that the probability of esopha-
gitis increased significantly (1.91-fold) for male gender,
1.3-fold per additional point on the GERD-Q score,
1.014-fold per each kg of weight added and 2.5-fold
when alcohol use increased to more than 20 units/
week (Table 3).
Discussion
The results of this observational, cross-sectional study
suggest that esophagitis and severe esophagitis are cur-
rently infrequent endoscopic diagnoses in this southern
European country. This is the first evaluation of the
factors related to esophagitis in a large sample of
Spanish patients (>1300 patients) undergoing upper
gastrointestinal endoscopy. Assessing a population as
large as this one in a southern European setting can
provide valuable epidemiological data on the factors
influencing esophagitis; it is known that genetic differ-
ences, differences in H. pylori prevalence and lifestyle
factors like obesity can influence the prevalence of
GERD in different geographical contexts.27 At present,
however, the reasons for the variability of its prevalence
are still not fully understood.27
In this regard, among the factors identified in other
studies,2,14 we found male gender, GERD-Q score,
weight and alcohol consumption to be positively
associated with the presence of esophagitis. Our results
corroborate those of previous studies.2,13,14,24,28
A recent study assessing the value of the GERD-Q
found an association between higher GERD-Q scores
and higher proportions of patients with reflux esopha-
gitis.24 However, the same study found that a low score
could not rule out the possibility of reflux esophagitis,
and also that a high score cannot exclude the possibility
of upper gastrointestinal malignancies. These findings
suggest that though GERD-Q may be used to diagnose
GERD, endoscopy is still needed for some patients in
populations with a high prevalence of upper gastro-
intestinal malignancies, like the Chinese.24 Based on
this finding and on our results, we think that further
studies should be performed in the Spanish population
to assess the exact correlation between GERD-Q score
and the presence of esophagitis, in order to validate the
questionnaire as a diagnostic tool for use in routine
clinical practice.
Other risk factors such as male gender, increased
weight and higher alcohol consumption were also
Table 2. Univariate analysis: Demographic, clinical and treatment
variables according to the presence/absence of esophagitis
Variable
Presence of
esophagitis
(n¼ 154)
No esophagitis
(n¼ 1207)
p
value
Age
(mean SD)
50.2 16.5 53.4 17.1 0.03
Gender
(male/female) (%)
16/7 84/93 0.000
BMI (kg/m2)
(mean SD)
26.8 5 26.1 5 0.049
Weight (kg)
(mean SD)
76.5 16 71.1 16 0.000
Height (cm)
(mean SD)
168.9 9.3 164.9 9.4 0.000
Increased waist
circumference
11.8% 7.8% 0.045
Alcohol (>20
units/week)
28.9% 10.8% 0.002
Smoking (>10
cigarettes/day)
14.3% 14.3% 1
Number of
comorbidities
0.29 0.7 0.4 0.8 0.07
PPIs 52.6% 54.6% 0.35
NSAID 15.6% 15.3% 0.5
AAS 6.9% 6.5% 0.51
GERD-Q Score
(Mean SD)
8.7 3.1 7.1 2.5 0.000
BMI: body mass index; GERD: gastro-esophageal reflux disease; PPI: proton
pump inhibitors; NSAID: nonsteroidal anti-inflammatory drug; AAS: acetyl
salicylic acid; SD: standard deviation.
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associated with the presence of esophagitis, as already
reported in other populations.2,13,28 However, we did
not find an association with smoking status.
We stress the strong association found between
esophagitis and high alcohol consumption, as already
reported in other populations in which (as in Spain) rou-
tine alcohol consumption is widespread.29,30 It is known
that consumption of large amounts of alcohol can pro-
mote regurgitation of acid into the esophagus and there-
fore cause GERD symptoms. Most individuals who
experience alcohol-related health problems are not
addicted to alcohol, but present with a hazardous pat-
tern of alcohol consumption.29 As a result, both alcohol
consumption and hazardous alcohol drinking should
always be considered as risk factors for esophagitis.
Interestingly, our study failed to find any significant
relationship between NSAID use and esophagitis.
NSAID use is known to induce gastroduodenal ulcers
and erosions, but our results corroborate previous stu-
dies31 that found that NSAIDs did not play an import-
ant role in the pathogenesis of erosive esophagitis.
The incidence of severe grades of esophagitis (C and
D) was lower than in other studies.27,32 Fifty percent of
patients were receiving a PPI before endoscopy; this high
rate of PPI use may have been the reason for the low
number of endoscopic lesions. It has already been
reported that patients with persistent dyspepsia treated
with a PPI have fewer endoscopic abnormalities than
patientswith dyspepsia receivingH2-receptor antagonists
and those receiving no therapy. For patients with partial
symptom relief, PPI therapy may mask the endoscopic
findings, most probably reducing the prevalence and the
severity of esophagitis in the patients receiving PPI. So,
many of the esophagitis observed should be considered
refractory cases not responding to PPI. It has been sug-
gested that the interruption of PPI for some weeks before
endoscopymay improve its diagnostic sensitivity,16,27 but
this affirmation remains largely unproven.
The widespread use of PPIs, along with the con-
founding by indication bias,33 might also explain why,
unlike previous studies,11,16 we did not find a significant
protective effect of PPIs for esophagitis.
Among the strengths of the present study are its
large sample size and its prospective, multicenter
design. Further research is now required in subgroups
of Spanish patients, especially in areas where the use of
PPIs is lower. A limitation of the study was that, as H.
pylori testing was not mandatory, we were unable to
adequately investigate the role of the infection in the
development of esophagitis. Assessment of risk factors
for Barrett’s esophagus in Spanish patients also
deserves further research.
Nevertheless, our study provides relevant data on
the prevalence and risk factors associated with esopha-
gitis, and has important clinical implications for the
assessment of the risk of esophagitis in routine clinical
practice in Spanish patients. We conclude that esopha-
gitis is infrequent in the Spanish population, and that
severe esophagitis is rare. Male gender, GERD-Q score,
weight increase and high alcohol consumption are the
main risk factors for esophagitis in our setting.
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